Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RN1201 in Newly Diagnosed Multiple Myeloma
NCT07652138Phase 1Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jul 2025
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RN1201 in multiple myeloma (MM), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Incidence and severity of treatment-emergent adverse events at 24 months and Dose-limiting toxicities at 28 days. Started Jul 2025; status: recruiting.
02
Drugs
RN1201
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07652138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07652138.